Dr. Richard LeBlanc

A hematologist and medical oncologist, he holds the Université de Montréal Myeloma Canada Chair on multiple myeloma at Hôpital Maisonneuve-Rosemont and is an assistant clinical professor at the Université de Montréal. He is responsible for research and development on multiple myeloma at the HMR and is in charge of the myeloma cell bank affiliated with the Quebec Leukemia Cell Bank. He is also the medical director of the clinical immunology laboratory at Hôpital Maisonneuve-Rosemont.

«  See the other members of the team




Dr. Jean Roy

A hematologist and department head of the hematology and oncology department at the HMR, he is a specialist in the transplantation of hematopoietic stem cells and an associate professor at the Université de Montréal. He actively participates in the specialized clinic on multiple myeloma and is a co-investigator of clinical studies on this disease.

«  See the other members of the team




Dr. Imran Ahmad

Dr Ahmad is a hematologist and associate professor of medicine. His expertise and fields of interest in cellular therapy cover hematopoietic stem cell transplantation, including conditioning regimens, graft-versus-host disease (GVHD), and prevention of relapse. He is also specialized in clinical research methodology.


  • Director, Cellular Therapy & Transplantation Program at HMR
  • Medical Lead, Cellular Therapy & Transplantation Clinical Research Unit at the HMR
Training:
  • MSc in Epidemiology, McGill University, 2011-2013
  • Fellowship in Hematopoietic Stem Cell Transplantation, Université de Montréal, 2007-2010
  • Residency in Internal Medicine and Hematology, Université Libre de Bruxelles (Brussels), 2002-2007
  • Doctor of Medicine, Université Libre de Bruxelles (Brussels), 1995-2002

«  See the other members of the team




Dr. Jean-Sébastien Claveau

Dr. Jean-Sébastien Claveau is a specialist in multiple myeloma and monoclonal gammopathies. He also has an interest in biostatistics and mass spectrometry. His research topics focus on the epidemiology and prognosis of patients with multiple myeloma or plasma cell dyscrasia.

• Fellowship: Mayo Clinic Rochester in USA, 2021-2023
• Starting position at Hôpital Maisonneuve-Rosemont: 2023

«  See the other members of the team